Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical announced positive Phase III trial results for Anlotinib Hydrochloride Capsule used with chemotherapy to treat advanced soft tissue sarcoma, meeting primary progression-free survival goals and showing a positive trend in overall survival. The promising results may lead to a new first-line treatment option in China, as the company prepares to submit a marketing application. This development marks a significant step in the treatment landscape for a condition with increasing incidence and limited treatment options.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
